QLNC-3A6 Di-Maleate

QLNC-3A6二马来酸盐

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameQLNC-3A6 Di-Maleate
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsStem cell growth factor receptor inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[4] 
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor betaTyrosine-protein kinase receptor FLT3 +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesQilu Pharmaceutical Co LtdQilu Antibiotics (Linyi) Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesQilu Pharmaceutical Co LtdQilu Antibiotics (Linyi) Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A